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Summary
Objective: This study was designed to assay cartilage oligomeric matrix protein (COMP) in equine synovial fluids and to compare the
concentration in synovial fluids from normal horses with joint diseased horses. The relationship between the COMP degradation and the
matrix metalloproteinase activity in synovial fluids was also investigated.
Design: Using COMP antigen prepared from equine articular cartilage and murine monoclonal antibody (12C4) raised against human COMP,
an inhibition ELISA was developed. COMP in equine synovial fluids from normal and diseased joints was quantified. Metalloproteinase
activities were evaluated in the same synovial fluids by a gelatin degradation ELISA. COMP fragments were evaluated qualitatively by
Western blotting.
Results: The COMP inhibition ELISA was reliable at concentrations of equine COMP between 62.5 and 2000 ng/ml. COMP values in joint
fluids in both aseptic and septic joint disease (19.7±15.3 and 16.1±11.2 g/ml, respectively) were significantly (P<0.001) lower than normal
(53.2±29.0 g/ml). The molecular sizes of COMP on immunoblots were different between normal and diseased synovial fluids; more
fragments were seen in diseased fluids. The aseptic (26.6±20.6%) and septic joint disease synovial fluids (36.1±37.5%) had significantly
higher (P<0.02 and 0.002, respectively) gelatinolytic activities than normal (13.6±13.7%). There was a negative correlation (R= −0.31,
P<0.002) between COMP level and gelatinase activity.
Conclusions: We conclude that the fragment pattern and the absolute COMP concentration maybe useful for monitoring joint disease, and
that COMP degradation in synovial fluids from progressed joint disease may be due to MMP gelatinolytic activity. © 2001 OsteoArthritis
Research Society International
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Cartilage oligomeric matrix protein (COMP), a macro-
molecule distributed abundantly through cartilage1,2, may
have potential for predicting progression of cartilage
destruction in diseases such as osteoarthritis (OA). Intact
COMP is pentameric, with five globular domains connected
to a central assembly domain by flexible strands3,4. Based
on its structural characteristics, COMP belongs to the
thrombospondin family4,5. While the precise role of COMP
in cartilage is not known, it appears to have a structural
function. COMP has been shown to mediate primary
chondrocyte attachment to matrix component6. Also, since
it was reported that mutations of the COMP gene cause
pseudochondroplasia7, it has been proposed that COMP
has a role in organizing matrix assembly in cartilage. In a
recent study, it was suggested that COMP influences the119organization of collagen fibrils through its C-terminal
globular domains8.
The use of COMP as a molecular marker for joint
diseases by measurement of levels in synovial fluid9 and
serum10 has been advocated. In studies of arthropathies,
COMP has usually been measured using either mono-
clonal antibodies or polyclonal antisera. The available
reagents appear to have different specificities. For
example, one described monoclonal antibody appears to
be specific for cartilage-derived COMP11, whereas poly-
clonal antisera can bind COMP from various cell sources
including synovial fibroblasts11,12. This may be important,
because COMP is not only cartilage-derived but is found
widely in other tissues, including synovium13,14 and
tendon15–17. Previous studies have demonstrated that
COMP levels detected with polyclonal antisera in synovial
fluids and serum were increased in the early stages of
OA9,18,19 and rheumatoid arthritis (RA)20,21, and subse-
quently decreased during disease progression. However,
while the use of particular antibodies may favor detection of
COMP from one particular source, it is impossible to
be confident that this is the case for all assay conditions
and all tissue samples. Thus, detected COMP must be
considered potentially to be derived from any source.
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fragments are contained in synovial fluid22 and cartilage
extracts23. The fragmentation is supposed to be the result
of degradation by proteinases, in which matrix metallo-
proteinases (MMPs) play an important role to maintain the
normal turnover of cartilage matrix molecules. Previous
clinical studies demonstrated that the release and activities
of MMPs in synovial fluid increase in OA24,25 and RA26,27,
and that there is a significant correlation between MMPs
and matrix turnover in OA28. While the involvement of
MMPs with COMP fragmentation has been suggested
in vitro and ex vivo29, this area needs further investigation.
In studies of joint disease, control samples from normal
joints are often difficult to obtain in man. For this reason, it
is valid to consider naturally occurring joint disease in other
species in which joint samples such as synovial fluids are
more readily available. Equine joint diseases are a serious
veterinary problem and serve as models for human
arthropathies. The most common type is osteoarthritis,
which is radiographically detected in advanced disease as
bone destruction or production (osteophytosis), joint space
narrowing and deformity30, and is strikingly similar to the
disease in man19,31. As in man, when radiographical
lesions are demonstrated, the disease is in an advanced
stage. Limited studies have been made to identify bio-
chemical markers indicating equine joint destruction before
radiographical alterations become evident. So far, gly-
cosaminoglycans including keratan sulfate32–35 in synovial
fluids and serum has been reported to have the potential to
indicate ongoing joint destruction. However, as in human
OA, such markers are not necessarily specific to joint
disease, or can be affected by a range of joint diseases35.
Thus, the information available for clinical practice is
restricted and joint markers more specific to cartilage
catabolism in OA should be investigated.
This study was performed to develop an assay system
for COMP in equine synovial fluids, using a monoclonal
antibody to COMP, and to compare the concentration in
synovial fluids from normal horses to those with joint
diseases. In addition, the relationship between the COMP
degradation and catabolic enzyme activities in synovial
fluids was investigated.Methods
PREPARATION OF EQUINE COMP
Fresh cartilage slices were obtained from normal
femoropatellar joints of an adult horse, which was
euthanazed for a reason other than orthopedic disease and
had no history of locomotor diseases. The tissues were
washed with distilled water and then kept frozen at −70°C
until processed.
COMP was isolated according to the method of Smith
et al. 17 with some modifications. Briefly, 25 g wet weight of
frozen cartilage slices was milled in liquid nitrogen to obtain
a fine particulate. The powdered tissue was suspended in
10 volumes of 4 M guanidine hydrochloride in 50 mM
sodium acetate buffer (pH 5.8) containing proteinase inhibi-
tors (10 mM EDTA, 100 mM 6-aminohexanoic acid, 5 mM
benzamidine-HCl, and 5 mM N-ethylmaleimide), homogen-
ized, and extracted at 4°C for 24 h with gentle stirring.
After centrifugation at 17 000 g at 4°C for 30 min, the
supernatant was separated, filtered, concentrated, and
dialysed against 7 M urea, 20 mM Tris-HCl, pH 8.0,
containing, 5 mM EDTA, 1 mM benzamidine, and 2 mMN-ethylmaleimide. This solution was applied to a DEAE
anion-exchange column (Mono Q HR5/5, Pharmacia). The
material bound on the column was eluted with a linear
gradient of 0–1 M sodium chloride in the same buffer. The
protein concentration of the eluent was determined by the
absorbance at 280 nm.
Aliquots from the eluted fractions were analysed by
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Based on its mobility under reduc-
ing and nonreducing SDS-PAGE conditions36, the fractions
eluted between 0.2–0.3 M sodium chloride were judged as
the COMP-rich fractions, pooled, and dialysed against
phosphate-buffered saline (PBS). The pooled solution was
further analysed by SDS-PAGE and Western blotting with a
monoclonal antibody to human COMP, and the protein
concentration determined37. This preparation (150 g/ml)
was subsequently used as an equine COMP standard.ANTI-COMP ANTIBODY
A murine monoclonal antibody (12C4) has been raised to
reduced and alkylated human COMP subunit as previously
described36. This antibody binds to native oligomeric
human COMP as well as its reduced subunit and
cross-reacts with bovine COMP (unpublished data).SDS-PAGE AND WESTERN BLOTTING
SDS-PAGE on 4–15% gradient gels was performed
according to the protocol of Laemmli38. After the electro-
phoresis, the gels were stained with Coomassie brilliant
blue R-250, or electrotransferred onto polyvinyl difluoride
(PVDF) membranes in Tris-glycine buffer (25 mM Tris/HCl,
192 mM glycine, pH 8.3, 20% methanol) at 70 V overnight
at 4°C. The membranes were blocked with 5% skimmed
milk in Tris buffered saline, pH 7.4, including 0.05% Tween
20 (TBS/Tween). Antigenic COMP was detected with the
murine monoclonal antibody (diluted 1:4000 in 2%
skimmed milk in TBS/Tween). Positive binding to alkaline
phosphatase conjugated goat anti-mouse IgG antibody
(A3688, Sigma) diluted 1:10,000 in 2% skimmed milk in
TBS/Tween was demonstrated by the development of
phosphatase reaction using 5-bromo-4-chloro-3-indolyl
phosphate nitro blue tetrazolium (BCIP/NBT, Sigma Fast/
B-5655) as a substrate.QUANTIFICATION OF ANTIGENIC COMP IN EQUINE SYNOVIAL
FLUIDS WITH INHIBITION ELISASynovial fluid samples
Equine synovial fluids (N=123) were provided by
veterinary surgeons at the Large Animal Hospital,
University of Liverpool. Normal synovial fluids (N=40) were
sampled either from joints judged to be free of any articular
pathology on clinical, radiological or arthroscopic examina-
tion, or from horses killed for medical problems unrelated
to joint disease that had no articular abnormality in the
sampled joints clinically and macroscopically at post mor-
tem. Synovial fluids from horses with clinical joint problems
were obtained either during diagnostic procedures or prior
to surgery. These synovial fluids were sorted into two
categories, namely aseptic joint disease (AJD, N=62) and
septic joint disease (SJD, N=21). The AJD group consisted
of OA (N=25), osteochondritis dissecans (OCD, N=16),
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sampled synovial fluids were centrifuged at 3500 g for
15 min at 4°C, the clear supernatant collected, aliquoted
and stored at −70°C until assay.COMP inhibition ELISA
An inhibition ELISA to quantify antigenic COMP was
designed according to the method reported previously36,39
with some modifications.Plate coating
Fifty microliters of purified horse COMP antigen, in a
coating buffer (20 mM sodium carbonate, 20 mM sodium
bicarbonate, 0.002% sodium azide, pH 10), was placed
into each well of 96-well microtitre ELISA plates (Dynatek)
at 0.6 g/ml, incubated for 2 h at room temperature and
then overnight at 4°C.Inhibition step
Equine COMP standards were prepared to give a range
of 8000–3.9 ng/ml by doubling dilutions in PBS, pH 7.0,
containing 0.05% Tween 20 (PBS/Tween, pH 7.0). Synovial
fluids were diluted 1/50 and 1/100 in the same buffer.
Diluted standards and synovial fluids were mixed with
monoclonal antibody 12C4 (ascites fluid diluted 1/40,000
in PBS/Tween, pH 7.0, 1% BSA) and incubated overnight
at 4°C.ELISA
Coated wells were washed three times (5 min each) with
PBS, pH 7.0 and blocked with 100 l/well of 5% BSA in
PBS, pH 7.0 for 1 h at room temperature. Blocked plates
were washed three times (2 min each) with PBS/Tween,
pH 7.0, and incubated with 100 l/well of the inhibition
mixture (monoclonal antibody plus COMP standard or
synovial fluid) for 1 h at room temperature and then for 1 h
at 4°C. The plates were washed three times (2 min each)
with PBS/Tween, pH 7.0 and incubated with 100 l/well of
alkaline phosphatase conjugated goat anti-mouse IgG
(A3688, Sigma) diluted 1/10,000 in PBS/Tween, pH 7.0,
1% BSA. After three 2-min washes with PBS/Tween,
pH 7.0, 100 l of glycine buffer (0.1 M glycine, 1 mM
MgCl2, 1 mM ZnCl2, pH 10.4) containing 1 mg/ml of
p-nitrophenyl phosphate (104-0, Sigma) was placed into
each well and the plates were left for color to develop. The
absorbance at 405 nm was read after 1 h using an ELISA
plate reader (Titertek Multiscan® PLUS). A semi-log
standard graph, where log10 (concentration of COMP
standards) was plotted against the readings, was con-
structed, and the concentration of antigenic COMP in the
synovial fluids was calculated using the linear portion of the
standard curve corresponding to the reliable range of
COMP concentration in this assay.GELATIN DEGRADATION ELISA
The degradation ELISA (to quantify gelatinase MMP
activity) was designed according to the protocol described
by Clegg et al. 25 with some modifications. Briefly, 96-well
ELISA plates were coated with 100 l of gelatin (0.5 g/mlin PBS) per well and incubated for 1 h at 37°C and
overnight at 4°C in a humidified chamber. After washing
with PBS, 100 l of synovial fluid diluted 1/40 in MMP buffer
(50 mM Tris/HCl, 5 mM CaCl2, 0.05% Brij 35, pH 7.6) was
added to each well and the plate incubated at 37°C for 2 h
in a humidified chamber. Following three washes with
PBS/Tween (0.05%), a rabbit anti-gelatin antisera diluted at
1:1000 in PBS/Tween was added and incubated at 37°C for
1 h in a humidified chamber. After removing the unbound
antibodies by three washes with PBS/Tween, the bound
primary antibodies were detected using anti-rabbit IgG-
alkaline phosphatase conjugate (1/20 000) and Sigma 104
phosphatase substrate, as a secondary antibody and sub-
strate, respectively. The absorbance at 405 nm (A405) was
read by ELISA reader. The amount of gelatin remaining on
the plate following incubation with a test sample, which was
obtained from the percentage reduction in A405 readings,
was calculated according to the following formula:
[(A405 of MMP buffer only)−(A405 of sample)]
×100/(A405 of MMP buffer only)IMMUNOBLOTTING OF SYNOVIAL FLUIDS
The synovial fluid samples for western blotting were
selected based on both the COMP concentration and the
gelatinolytic activity. The samples were pre-treated with
hyaluronidase from bovine testis according to the method
described by Neidhart et al. 22 prior to the assay. The tested
samples were applied to 4–15% SDS-polyacrylamide gel.
Following SDS-PAGE, the gels were transferred to blotting
membranes to detect antigenic COMP fragments with
12C4.STATISTICS
All quantitative data were expressed as mean (S.D.). The
statistical differences in COMP concentration among
some categories were analysed by factorial ANOVA, and
Scheffe´’s method was used for simultaneous multiple
comparisons. A P-value less than 0.05 was considered
significant.ResultsANALYSIS OF EXTRACTED EQUINE CARTILAGE COMP
Fractions eluted from the DEAE column separation of
the equine cartilage extract between 0.2–0.3 M sodium
chloride contained abundant protein which migrated at high
molecular weight (512 kDa) in 4–15% PAGE gel under
non-reducing condition (Fig. 1). Under reducing conditions,
a protein band with the estimated molecular weight (MW) of
101 kDa stained prominently with Coomassie blue (Fig. 1).
Western blotting of equine COMP showed that both the
non-reduced oligomeric and reduced monomeric COMP
bands on the immunoblots were recognized by the mono-
clonal antibody to human COMP (12C4) (Fig. 2). Antibody
12C4 also identified fainter protein bands (MW 85, 69, 64,
and 61 kDa) under reducing conditions (Fig. 2).MEASUREMENT OF ANTIGENIC COMP IN SYNOVIAL FLUIDS WITH
INHIBITION ELISA
To quantify COMP in equine synovial fluids, an inhibition
ELISA was designed using the purified equine cartilage
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on the inhibition curve produced by the standard COMP
from equine cartilage, the reliability of the ELISA assay was
confirmed at the concentration between 62.5 and 2000 ng/
ml. The linear portion of the curves, created by diluting
equine synovial fluids between 1/3 and 1/192, was parallel
to that of the standard curve derived from isolated horse
cartilage COMP. The curve produced by synovial fluid from
an osteoarthritic joint shifted to the right of the profile from
normal synovial fluid.
The results for COMP measurements in horse synovial
fluids are shown in Fig. 4. The mean COMP value in the
normal joint fluids was 53.2±29.0 g/ml, and this was
significantly (P<0.001) higher than both of AJD and SJD
joints (19.7±15.3 and 16.1±11.2 g/ml, respectively).
There were no significant differences between the values
for AJD and SJD. The COMP concentration in AJD joints
were analysed further by sorting the samples according to
the clinical diagnosis. The mean COMP values in OA, OCD
and intraarticular fracture were higher than in synovitis and
SJD, but no statistically significant differences were shown.Fig. 1. Fractions eluted from the DEAE column separation of the equine cartilage extract between 0–1.0 M sodium chloride. COMP
containing fractions (bar) pooled between 0.2–0.3 M sodium chloride and analysed by SDS-PAGE. On 4–15% gradient gel, COMP pentamer
can be seen close to stacking level (estimated 512 kDa) under nonreducing condition. The monomer (101 kDa) was detected under reducing
condition.Fig. 2. Western blot analysis of COMP antigen separated by
SDS-PAGE with monoclonal antibody 12C4. Under non-reducing
condition the COMP pentamer is demonstrated as the strong band
at the start of the separating gel. Under reducing condition, an
intense band consistent with the migration of COMP monomer and
some fainter bands (85, 69, 64, and 61 kDa) are produced.RELATIONSHIP BETWEEN COMP CONCENTRATION AND
GELATINOLYTIC ACTIVITY IN SYNOVIAL FLUIDS
We evaluated the gelatinase activity in 117 samples of
synovial fluid tested in the COMP ELISA. The aseptic
(26.6±20.6%) and septic synovial fluids (36.1±37.5%)
had significantly higher (P<0.02 and P<0.002, respect-
ively) gelatinolytic activities than normal joint fluids
(13.6±13.7%), as shown in Fig. 5. As the percentage
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according to the clinical diagnosis, the averages in OCD
and synovitis were higher than others but there were no
statistically significant differences. Between the COMP
concentration and the percentage degradation of gelatin
(converted logarithmic scale) in the samples, a negative
correlation (R= −0.31) was seen, which was significant
(P<0.002) (Fig. 6).IMMUNOREACTIVE COMP FRAGMENTS IN SYNOVIAL FLUIDS
(FIG. 7)
To identify COMP fragments in synovial fluids, 12
samples each from normal and diseased joints were
selected. These were selected for a range of COMP and
gelatinase activities. In Western blots of both normal and
diseased synovial fluids, some COMP fragments were
seen. Fragments with molecular weights of less than
60 kDa were not found. The fragment sizes in normal
synovial fluids were 520, 424, 330, 191, 62 kDa. For
diseased samples these were 516, 421, 280, 177, 136,
101, and 67 kDa. The relative proportion of the fragments
were clearly different between normal and diseased
synovial fluids. While in the normal samples the high-
molecular-weight molecules (the size of intact COMP) were
apparent, they were less readily seen in diseased synovial
fluids. On the other hand, in diseased samples there were
more bands, which were prominent, apparent in the range
of 100 to 250 kDa. In septic samples, particularly, the
high-molecular-weight COMP (516 kDa) was not seen; only
fragments were detected.Fig. 3. The inhibition curve obtained using the standard COMP
from equine cartilage, and the synovial fluids from normal and
diseased joints. The linear portion is shown between 62.5 and
2000 ng of COMP standard/ml. The linear portion of the curves
from equine synovial fluids was parallel to the standard curve. The
curve of synovial fluid from diseased joints shifts to the left of the
normal synovial fluid.0
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Fig. 4. COMP concentration (mean±S.D.) in horse synovial fluids.
The COMP concentrations in aseptic joint disease fluids were
analysed further by sorting the samples according to the clinical
diagnosis (A). The COMP value in the normal joint fluids is
significantly higher than either aseptic or septic joints (B). * shows
statistical difference (P<0.001) vs normal synovial fluids. OA;
osteoarthritis, OCD; osteochondritis dissecans.Discussion
This work identified COMP in chromatographic fractions
of guanidine hydrochloride extracts of equine articular
cartilage. Identity was based on electrophoretic mobility in
SDS-PAGE and the specificity of a murine monoclonal
antibody to human COMP. Pentameric equine COMP was
seen as a 512 kDa band in SDS-PAGE under non-reducing
conditions, while reduced COMP had a molecular mass of101 kDa. These sizes are consistent with those identified
for COMP in a previous study in other equine tissues,
including tendon, ligament, scarred skin and granulation
tissue17. A murine anti-human COMP monoclonal antibody
(12C4) recognized both non-reduced and reduced COMP
protein. The sizes of some smaller and fainter reduced
bands detected by 12C4 are similar to previously reported
degradation products of purified COMP22.
The concentration of COMP, measured by inhibition
ELISA, was significantly lower in synovial fluids from dis-
eased joints compared with normal joints. However, no
significance was shown for the differences between septic
and aseptic joint disease synovial fluids. Thus, while
decreased synovial fluid COMP concentrations may indi-
cate pathological changes, it is not possible to differentiate
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Fig. 5. Degradation (%) of gelatin (mean±S.D.) in horse synovial
fluids. The percentage in AJD joints were analysed further by
sorting the samples according to the clinical diagnosis (A). The
percentage gelatin degradation in either aseptic or septic joints
was significantly higher than the normal joints (B). Statistical
difference was seen (P<0.002* and 0.02†, respectively) vs
normal synovial fluids. OA; osteoarthritis, OCD; osteochondritis
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Fig. 6. COMP concentration and percentage degradation of gelatin
in equine synovial fluids. A negative correlation is shown (N=117,
R= −0.31, P<0.002).between different disease conditions. Immunoblotting did
identify qualitative differences between breakdown product
patterns in aseptic and septic joint disease fluids. However,
these differences were not consistent within or between the
aseptic and septic groups.
In previous studies relating the progression of joint
disease with COMP levels in synovial fluid31,40 or
serum18,21,41,42, the COMP level in synovial fluid and
serum from patients with joint diseases has been shown to
be higher than in healthy joints and normal sera, respect-
ively. It has also been suggested that COMP in synovial
fluids increases in the early stage of joint disease and then
decreases in patients with advanced joint damage9,39. The
discrepancy between previous reports and our results may
be dependent on the ELISA protocol, particularly in thechoice of primary antibodies used to detect COMP. While in
previous clinical studies COMP has been measured using
predominantly rabbit polyclonal antisera, we used a murine
monoclonal antibody 12C4 for the assay. It has been
reported that there is a difference in molecular weight of
COMP-derived antigens recognized by polyclonal and
some particular monoclonal antibodies in human synovial
fluid11. For example, in synovial fluid from a healthy person,
polyclonal antibody recognized low-molecular-weight frag-
ments as well as oligomeric COMP, while a monoclonal
antibody (18G3) showed a high affinity for oligomeric forms
of COMP exclusively, with no binding of low-molecular-
weight COMP fragments11. Similarly, on Western blots of
nonreduced healthy synovial fluids22, polyclonal antibody
detected predominantly smear fractions (100–150 kDa)
and low-molecular-weight fragments (70–100 kDa) but no
oligomers. Interestingly, our immunoblot of normal synovial
fluids from equine joints showed that the murine mono-
clonal anti-COMP antibody (12C4) can recognize intact
COMP and partially degraded COMP oligomer, but not the
very low-molecular-weight fragments. This antibody also
detected, in samples from diseased joints, degraded low-
molecular-weight fragments, while high molecular weight
bands were fainter or not detected. Therefore, we propose
that the COMP concentration measured using ELISA with
monoclonal antibody 12C4 predominantly reflects the level
of intact or less degraded high-molecular-weight COMP
antigen in synovial fluids, and does not detect small frag-
ments of COMP which lose their antigenicity as COMP
degradation progresses to a certain level. This is consistent
with the fact that the epitope recognized by monoclonal
antibody 12C4 is located near the C-terminus of COMP
subunit, i.e. either in a C-terminal globular domain or in a
domain of calmodulin-like repeats and, hence, can be
removed by proteolytic cleavage of the COMP subunit
which would trim the molecule from its C-terminus.
An alternative explanation may result from differences in
antibody specificity. Hummel et al. who used another
monoclonal antibody to human COMP (18G3), have sug-
gested that particular monoclonal antibodies may only
detect cartilage-derived COMP and may be unable to
detect COMP from other sources11. Additionally, polyclonal
antibodies bind synovial ﬁbroblast- as well as chondrocyte-
derived COMP11,12,14. While we have no data as to the
antigenicity of different tissue-speciﬁc COMPs to our anti-
body, it is plausible that 12C4 detects predominantly
cartilage-derived COMP.
Increases in the activities of several MMPs, including
MMP-1, 3, 9, and 13, have been suggested as a potential
causes of COMP degradation29. In particular, MMP-9
can efficiently degrade cartilage-derived COMP into more
fragments than other MMPs29. This study showed sig-
niﬁcantly higher gelatinolytic activities in diseased, com-
pared to normal, joint ﬂuids. A slight negative regression
(R-squared=0.31; P<0.002) between COMP concentration
and gelatinase activity suggests that increased digestion by
Fig. 7. Immunoblots of synovial ﬂuids from normal and diseased joints. The similar sizes of COMP fragments are found in both of normal and
diseased samples. While the high-molecular-weight fragments (>400 kDa) predominated in normal, more degraded fragments at the range
of 100 to 250 kDa were shown in diseased samples. Interestingly, one sample (lane 8) of normal synovial ﬂuids shows similar fragment
pattern to the diseased sample (lane 1). Lane 13 in blots of normal synovial ﬂuids; COMP standard extracted from horse cartilage.
Figures for COMP concentration were determined using the inhibition ELISA; percentages gelatin digestion were measured by gelatin
degradation ELISA.
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of COMP.
In conclusion, our findings indicate that the inhibition
ELISA for equine COMP, in its present form, is a potentially
valuable tool in the study and possibly the diagnosis of
equine joint disease. There are clearly issues which remain
to be resolved. In particular, it will be important to determine
the specificity of our antibody to COMP from different
sources. This will help lead to an explanation for the
differences between our findings of a reduction in COMP in
disease and those of others who identified an increase.
Finally, although we have shown a negative correlation
between COMP and gelatinase activity, further and exten-
sive studies will be required to establish or reject the
hypothesis that gelatinases are actually responsible for
COMP degradation within cartilage.Acknowledgments
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